56427-77-1

Upstream product

• 14920-81-1 methyl 2,6-dimethylbenzoate 
• 632-46-2 2,6-dimethylbenzoic acid 
• 67-56-1 methanol 
• 635316-54-0 2-bromomethyl-6-methyl-benzoic acid 
• 755030-83-2 2-bromomethyl-6-methylbenzoyl bromide 

Downstream Products

• 108734-57-2 2-Benzenesulfonylmethyl-6-methyl-benzoic acid methyl ester 
• 96964-50-0 1-methyl-2-(bromomethyl)-3-<(phenylsulfonyl)-methyl>benzene 
• 96964-71-5 3-Ethyl-5-methyl-[1,2]naphthoquinone 
• 96964-49-7 1-methyl-2-(hydroxymethyl)-3-<(phenylsulfonyl)-methyl>benzene 
• 96964-58-8 4-Benzenesulfonyl-2-ethyl-8-methyl-3-oxo-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid methyl ester 
• 96964-59-9 4-Benzenesulfonyl-2-ethoxycarbonylmethyl-8-methyl-3-oxo-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid methyl ester 
• 452978-83-5 methyl 2-(acetoxymethyl)-6-methylbenzoate 
• 303225-12-9 isobutyl 2-[3-(methoxy)-phenylsulfanylmethyl]-6-methyl-benzoate 
• 1416990-05-0 3-(7-methyl-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 870539-42-7 methyl 2-{3-[2-(4-fluorophenyl)oxazol-4-yl-methoxy]cyclohexyloxy}-6-methylbenzoate 
• 304025-01-2 methyl 2-methyl-6-[4-(quinolin-2-ylamino)-butoxymethyl]-benzoate 
• 304024-99-5 methyl 2-[4-(acetyl-quinolin-2-ylmethyl-amino)-butoxymethyl]-6-methyl-benzoate 
• 304024-89-3 methyl 2-methyl-6-[3-(quinolin-2-ylmethoxy)-propoxymethyl]-benzoate 

Relevant academic research and scientific papers

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.

Substituted Indole Compounds

Substituted indole compounds corresponding to the formula I: In which R8, R9a, R9b, R10, R11, R200, R210, A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES

The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated

Therapeutic uses of tri-aryl acid derivatives

The use of triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives

Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives A process is described for preparing chiral, nonracemic, cis-configured 1,3-disubstituted cyclohexanols of the formula (I) where the radicals are as defined, by

2-BROMOMETHYL-6-METHYL-BENZOIC ACID AND A PROCESS FOR THE PREPARATION THEREOF

The present invention refers to a process for the preparation of 2-bromomethyl-6-methyl-benzoic acid (I) and derivatives thereof by selective bromination of 2,6-dimethylbenzoic acid (II) with sodium bromate and hydrobromic acid in the presence of light.

Therapeutic uses of di-aryl acid derivatives

The use of diaryl acid derivatives of formula (I) or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

WATER-SOLUBLE TRIAZOLE FUNGICIDE

A triazole compound of the general formula (I) or a pharmacologically acceptable salt thereof: [wherein,X represents a group of formula X-OH which has antifungal activity,L represents a -(adjacently substituted C6-C10 aryl)-CH2-group and the like, andR represents a -P(=O) (OH)2 group and the like.

Aromatic Spiranes XXI [1]: Syntheses of Methyl Substituted Phthalaldehydic Acids and their Ethyl and Methyl Esters as Synthones for Syntheses of Methylated 2,2′-Spirobiindandiones

The isomeric methyl phthalaldehydic acids 11 were obtained from phthalides 4 by bromation (NBS) to the 3-bromo derivatives 7 and subsequent hydrolysis with water. 4 in turn were accessible from dimethyl methyl benzoates 1 by dibromination with NBS and subsequent thermical cyclization to the bromo derivatives 3 which, on catalytic dehalogenation, afforded the phthalides 4. Reaction of 11 with methanol or ethanol gave the pseudo-esters 13 and 14, resp. Short treatment of 11 with diazomethane on the other hand yielded the methyl formyl benzoates 15b to 15e. Prolonged reaction (several hours) gave the oxiranyl compounds 17; in addition, the acetonyl derivatives 18 were also found, obviously formed by a double methylene insertion into 15. All reactions proceeded with good to excellent yields.

6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives

6,11-Dihydrodibenz[b,e]oxepin-acetic acids and derivatives having the general formula STR1 are prepared by multi-step sequences. X is C=O, CHCl, CHBr, CH2 or CHOR4 ; Y is alkyl or alkoxy of 1 to 4 carbon atoms, halogen or trifluoromethyl; n is 0, 1, 2 or 3; Z is COOR5, CH2 OR5, CONR25 or CONHOR5 ; and R1 -R5 are hydrogen or alkyl of 1 to 4 carbon atoms. These compounds and the physiologically tolerable salts thereof are useful as antiinflammatory and analgesic agents.